Authors of a new report on cannabinoids and atopic dermatitis—also called eczema—say their study demonstrated that an ointment including cannabidiol (CBD) and cannabigerol (CBG) was “effective in reducing itching and improving the quality of life of patients…leading to symptom remission in some cases.”
Published in the journal Clinical, Cosmetic and Investigational Dermatology, the original research looked a number of metrics of skin health, including hydration sebum level and pH, in nine adult patients diagnosed with atopic dermatitis (AD).
The transdermal ointment was used as an alternative “to conventional auxiliary therapies during both flare-ups and remission” from May to July 2022, the team wrote. “The results we achieved included improved skin hydration, sebum level, and TEWL [water loss] as well as reduced erythema [redness] in the studied areas (forearms).”
AD, or eczema, “is the most common, chronic, and relapsing non-contagious inflammatory skin condition,” authors noted.
The ointment itself consisted of 30 percent CBD, 5 percent CBG, hemp seed oil and cholesterol. Patients were instructed to “apply a generous layer of the ointment to the same site (the forearms) once daily before sleep and to cover the area with a wet wrap dressing to enhance its effectiveness and protect bedsheets,” the report says.
Photos and other metrics observed a marked improvement in skin appearance and health over a three-month period. Authors wrote that their preliminary analysis of the results “showed that the topical delivery of the ointment compounded with Cannabis Sativa L. var. sativa oil, cholesterol ointment, 30% CBD, and 5% CBG led to the remission of skin lesions on the forearms of the included patients.”
Patients who better adhered to the treatment regimen, they added, demonstrated greater improvement.
“In the course of the therapy, patients adhering to the topical cannabinoid regimen achieved satisfactory skin parameters, including normal hydration and sebum levels, as well as improved TEWL and erythema,” the study says, “as opposed to patients who reported failure to comply with the regimen owing to the fatty texture of the formulation, despite the instructions they received.”
Hellbound and Down 